Abstract

A continuous-flow process is provided for separating at least two components from a mixture of components. The mixture is provided in a counter-current flow comprising a first phase flowing in an opposite direction with respect to a second phase, the first phase being immiscible with and/or separated from the second phase. A plurality of stages are provided along the counter-current flow for exchanging the at least two components between the phases. Each stage is associated with a partition coefficient for each or the component between the first and second phase, and a first-to-second-phase flow rate ratio. The counter-current flow comprises, for each of the at least one component, an accumulation region. The partition coefficient and/or the flow rate ratio of stages at opposite sides of the accumulation region are adapted for inducing, at each of said stages, a net flux of the component along the counter-current flow, such that the direction of said net flux is opposite for stages at opposite sides of the accumulation region points towards the accumulation region. The component can then be removed from the accumulation region and from the counter-current flow.

IPC Classes  ?

• B01D 11/04 - Solvent extraction of solutions which are liquid
• C22B 3/26 - Treatment or purification of solutions, e.g. obtained by leaching by liquid-liquid extraction using organic compounds

Abstract

The present invention relates to a method for obtaining potato with lower sugars content by site-directed nucleotide substitution, and also relates to a method for generating site- directed nucleotide substitution and fragment substitution.

IPC Classes  ?

• C12N 9/22 - Ribonucleases
• C12N 9/26 - Hydrolases (3.) acting on glycosyl compounds (3.2) acting on alpha-1, 4-glucosidic bonds, e.g. hyaluronidase, invertase, amylase
• C12N 15/82 - Vectors or expression systems specially adapted for eukaryotic hosts for plant cells

Abstract

A computer-assisted method for the dimensioning of a magnetron cavity for an atomic clock, in particular for a hydrogen maser, the cavity being substantially cylindrical and including at least two curved electrodes disposed along a circular arc and delimiting a substantially cylindrical space of predetermined radius r, the cavity also including a substantially cylindrical storage bulb of radius rB disposed in said space such that there is a radial interstice ei between the at least two electrodes and the storage bulb.

IPC Classes  ?

• H03L 7/26 - Automatic control of frequency or phaseSynchronisation using energy levels of molecules, atoms, or subatomic particles as a frequency reference
• G04F 5/14 - Apparatus for producing preselected time intervals for use as timing standards using atomic clocks

Abstract

The present invention relates to a binding agent capable of specifically binding to and inhibiting competitively a neutrophil elastase, which binding agent comprises an immunoglobulin single variable domain (ISVD), as well as related products, methods, and uses, such as in particular methods and uses aimed at the prevention, treatment, or diagnostics of inflammatory diseases.

IPC Classes  ?

• A61P 11/00 - Drugs for disorders of the respiratory system
• C07K 16/40 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against enzymes
• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum

Abstract

The present invention concerns new peptides and polypeptides that bind to IKK and inhibit the NF-κB signaling pathway. The present invention also relates to a method of inhibiting the NF-κB signaling pathway and a method of identifying small molecules targeting IKK dimers. The present invention further provides pharmaceutical compositions and their use in a method for treating and/or preventing a disorder regulated by the NF-κB signaling pathway.

IPC Classes  ?

• C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
• A61K 38/00 - Medicinal preparations containing peptides
• A61P 35/00 - Antineoplastic agents

Abstract

A gas sensor device (10) is configured to detect boar taint in a gas sample of volatised boar fat (5) by using a difference between i) a change in a first signal of a first sensor (2) over a sampling period and ii) a change in a second signal of a second sensor (2) over a sampling period to differentiate between a presence and an absence of boar taint. The gas sensor device (10) comprises a hemispherical enclosure (3) configured to be put in close contact with the surface of the boar fat (5) in order to sample VOCs being volatised from the boar fat (5). The VOCs are volatised by placing a heating device (1) in contact with the surface of the boar fat (5) and heating up to a temperature in the range from 200°C to 500°C. The gas sensor device (10) is designed to be used at line on the production line of a slaughterhouse.

IPC Classes  ?

• G01N 33/00 - Investigating or analysing materials by specific methods not covered by groups
• G01N 33/12 - MeatFish
• G01N 1/22 - Devices for withdrawing samples in the gaseous state

Abstract

The invention provides a complex comprising at least one hydrophobic active agent, an ionic polymer comprising a repetitive unit of formula (I): The invention provides a complex comprising at least one hydrophobic active agent, an ionic polymer comprising a repetitive unit of formula (I): The invention provides a complex comprising at least one hydrophobic active agent, an ionic polymer comprising a repetitive unit of formula (I): wherein R1 represents a hydrogen atom or a straight or branched chain alkyl group, preferably a straight or branched chain alkyl group comprising from 1 to 6 carbon atoms, for example a methyl group; R2 represents a straight or branched chain alkyl group which is substituted by a group which may have a positive charge at a physiological pH wherein the ionic polymer is a homopolymer or a random copolymer, wherein the repetitive unit of formula (I) in a random copolymer comprises (dimethylamino)ethyl methacrylate, wherein the molar proportion of (dimethylamino)ethyl methacrylate repetitive units to the total number of repetitive units in a random copolymer is greater than 50%, and wherein the at least one hydrophobic active agent has a molecular weight of from 100 to 1500 g/mol; a complex for use in a method of medical treatment; a pharmaceutical composition; and a method of preparing a complex or pharmaceutical composition according to the invention which method comprises the steps of: The invention provides a complex comprising at least one hydrophobic active agent, an ionic polymer comprising a repetitive unit of formula (I): wherein R1 represents a hydrogen atom or a straight or branched chain alkyl group, preferably a straight or branched chain alkyl group comprising from 1 to 6 carbon atoms, for example a methyl group; R2 represents a straight or branched chain alkyl group which is substituted by a group which may have a positive charge at a physiological pH wherein the ionic polymer is a homopolymer or a random copolymer, wherein the repetitive unit of formula (I) in a random copolymer comprises (dimethylamino)ethyl methacrylate, wherein the molar proportion of (dimethylamino)ethyl methacrylate repetitive units to the total number of repetitive units in a random copolymer is greater than 50%, and wherein the at least one hydrophobic active agent has a molecular weight of from 100 to 1500 g/mol; a complex for use in a method of medical treatment; a pharmaceutical composition; and a method of preparing a complex or pharmaceutical composition according to the invention which method comprises the steps of: (a) dissolving the hydrophobic active agent and the ionic polymer in one or more non-aqueous solvents to form the complex wherein the one or more non-aqueous solvents are miscible with water; and The invention provides a complex comprising at least one hydrophobic active agent, an ionic polymer comprising a repetitive unit of formula (I): wherein R1 represents a hydrogen atom or a straight or branched chain alkyl group, preferably a straight or branched chain alkyl group comprising from 1 to 6 carbon atoms, for example a methyl group; R2 represents a straight or branched chain alkyl group which is substituted by a group which may have a positive charge at a physiological pH wherein the ionic polymer is a homopolymer or a random copolymer, wherein the repetitive unit of formula (I) in a random copolymer comprises (dimethylamino)ethyl methacrylate, wherein the molar proportion of (dimethylamino)ethyl methacrylate repetitive units to the total number of repetitive units in a random copolymer is greater than 50%, and wherein the at least one hydrophobic active agent has a molecular weight of from 100 to 1500 g/mol; a complex for use in a method of medical treatment; a pharmaceutical composition; and a method of preparing a complex or pharmaceutical composition according to the invention which method comprises the steps of: (a) dissolving the hydrophobic active agent and the ionic polymer in one or more non-aqueous solvents to form the complex wherein the one or more non-aqueous solvents are miscible with water; and (b) progressively replacing the one or more non-aqueous solvents with water.

IPC Classes  ?

• A61K 47/58 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
• A61K 31/12 - Ketones
• A61K 31/122 - Ketones having the oxygen atom directly attached to a ring, e.g. quinones, vitamin K1, anthralin
• A61K 31/7048 - Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin
• A61K 31/7064 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
• A61K 47/61 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof

Abstract

The present invention relates to a polymer derivative comprising a hydrophilic segment obtained from the polymerisation of N-methyl-N- vinylacetamide (PNMVA), coupled to at least one hydrophobic segment, said hydrophobic segment comprising at least one aliphatic chain of 8 to 28 carbon atoms. The present invention also relates to a method for preparing such polymer derivative. Lipid nanoparticles modified by PNMVA-based derivatives were prepared and advantages were shown compared to PEgylated lipid nanoparticles. The present invention also relates to the medical use of lipid nanoparticles containing PNMVA-based derivatives, particularly to the use of nucleic acid delivery, for example SiRNA delivery to target tumor cells.

IPC Classes  ?

• C08F 126/02 - Homopolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a single or double bond to nitrogen or by a heterocyclic ring containing nitrogen by a single or double bond to nitrogen
• C08F 8/32 - Introducing nitrogen atoms or nitrogen-containing groups by reaction with amines
• C08F 8/44 - Preparation of metal salts or ammonium salts

Abstract

A microfluidic device for use in field of droplet microfluidics is disclosed. The microfluidic device can manipulate a discrete element, for example a droplet. The discrete element may include a medium and a component. The microfluidic device may include a main microfluidic channel, some stopping elements and an attractive mechanism that may retain, physically and in a releasable way, the component at a given location in the main microfluidic channel. The discrete element may be split into a first and second parts in such a way that the component ends in the second parts. The microfluidic device. may be used especially for a single-cell analysis.

IPC Classes  ?

• B01L 3/00 - Containers or dishes for laboratory use, e.g. laboratory glasswareDroppers

Abstract

The present invention relates to a breast implant (1) and to a process to produce at least part of it by additive manufacturing. The breast implant (1) includes a first part (10), more rigid, along an axis (5), and a second part (20), more resorbable, around the first part (10). The implant (1) is bio- absorbable and elastically deformable in a direction perpendicular to the axis (5). The implant (1) is suitable for colonization by the vascular network with fat cells (differentiated cells) and their precursors (undifferentiated cells).

IPC Classes  ?

• A61F 2/12 - Mammary prostheses

Abstract

aa of at least 20 when measured in acetonitrile, wherein the reaction is carried out at a temperature of at least 90 °C and up to 150 °C, and wherein the first channel has an inner hydraulic diameter of from 100 to 2000 μm, and a pressure in the first channel is adapted to keep the solvent liquid.

IPC Classes  ?

• C07D 317/36 - Alkylene carbonatesSubstituted alkylene carbonates
• C07C 68/04 - Preparation of esters of carbonic or haloformic acids from carbon dioxide or inorganic carbonates
• C07C 69/96 - Esters of carbonic or haloformic acids

Abstract

Fluidic unit (2), preferably microfluidic, for trapping a discrete element (10) in a liquid sample (100a) and comprising: • a well (3) for receiving a volume of a liquid (100) comprising the discrete element (10); • a well output conduit (4); • a metering chamber (5) in fluid communication with the well (3) through said well output conduit (4), for metering a liquid sample (100a) of the volume of the liquid (100) received from the well (3); • an obstructable waste output conduit (6) for evacuating an excess portion (100b) of the volume of the liquid (100) from the metering chamber (5).

IPC Classes  ?

• B01L 3/00 - Containers or dishes for laboratory use, e.g. laboratory glasswareDroppers

Abstract

The present invention relates to medical imaging, disease monitoring and theranostic approaches in neoplastic diseases of certain anti-CD38 single-domain antibodies (sdAb).

IPC Classes  ?

• A61K 51/10 - Antibodies or immunoglobulinsFragments thereof
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61K 51/04 - Organic compounds
• A61P 35/00 - Antineoplastic agents
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer

Goods & Services

Business performance management software; Reporting software; Software for identifying, monitoring, managing, analyzing, compiling, visualizing and reporting data; Computer software platforms, recorded or downloadable; Downloadable computer software applications for mobile devices; Downloadable educational course materials. Business advisory services relating to company performance; Business organization advice; Advertising, marketing and promotional consultancy, advisory and assistance services; Business auditing; Statistical analysis and reporting services for business purposes; Compilation of statistical and mathematical data; Computerized auditing. Software as a service (SAAS) featuring business performance management software; Software as a service (SAAS) services featuring software for data collection, data management, data analysis, process and data automation, data reporting and data interpretation and collaboration; Quality audit; Computer programming services for commercial analysis and reporting; Development of databases.

Abstract

The present disclosure relates to a composition for promoting plants growth and/or for protecting plants against at least one plant pest and/or one plant disease, the composition comprising simultaneously at least one bacteria of the genus Bacillus producing antifungal lipopeptides, at least one fungi of the genus Trichoderma, and at least one nitrogen mineral source. The present disclosure also relates to the use of such a composition and to a method for obtaining such a composition. The present disclosure also relates to a co-culture medium for producing at least in part such a composition.

IPC Classes  ?

• A01N 63/22 - Bacillus
• A01N 37/44 - Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids containing at least one carboxylic group or a thio-analogue, or a derivative thereof, and a nitrogen atom attached to the same carbon skeleton by a single or double bond, this nitrogen atom not being a member of a derivative or of a thio-analogue of a carboxylic group, e.g. amino-carboxylic acids
• A01N 63/38 - Trichoderma
• A01P 1/00 - DisinfectantsAntimicrobial compounds or mixtures thereof
• A01P 3/00 - Fungicides
• A01P 5/00 - Nematocides
• A01P 7/04 - Insecticides
• A01P 15/00 - Biocides for specific purposes not provided for in groups
• A01P 21/00 - Plant growth regulators
• C05C 5/02 - Fertilisers containing other nitrates containing sodium or potassium nitrate

Abstract

A medical device comprising one or more polyhydroxyurethane (PHU) and a method of manufacturing thereof. Use of the medical device to load and release or graft bioactive molecules, particularly antimicrobial, anti-thrombotic and anticalcification molecules

IPC Classes  ?

• A61L 27/18 - Macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
• A61L 27/34 - Macromolecular materials
• A61L 29/06 - Macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
• A61L 29/08 - Materials for coatings

Abstract

The present invention relates to a curable isocyanate-free formulation for preparing a polyurethane self-blowing foam comprising at least one multifunctional cyclic carbonate having at least two cyclic carbonate groups at the end of the chain (compound A), at least one multifunctional amine (compound B), water or/and a water source and optionally at least one catalyst (compound D), to a process for preparing said foams and to the thus obtained foams, to a process for recycling the obtained foams and to the thus recycled foams.

IPC Classes  ?

• C08J 9/02 - Working-up of macromolecular substances to porous or cellular articles or materialsAfter-treatment thereof using blowing gases generated by the reacting monomers or modifying agents during the preparation or modification of macromolecules
• C08J 9/08 - Working-up of macromolecular substances to porous or cellular articles or materialsAfter-treatment thereof using blowing gases generated by a previously added blowing agent by a chemical blowing agent developing carbon dioxide
• C08G 71/04 - Polyurethanes

Abstract

The present invention relates to a compound of formula I, a stereoisomer, a tautomer and/or a dimer thereof or a salt thereof, (I) wherein M is a metal among the group of Mg, Cu and Zn; R1is a methyl group or a formyl group; R2 is a carboxylic acid or a methyl ester, for use in the prevention or treatment of a bacterial infection in a subject and to the uses of such compound as antibacterial agent or particularly as preserving agents, and to processes for obtaining a microalgal extract comprising such compounds.

IPC Classes  ?

• A61K 31/409 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
• A61K 8/00 - Cosmetics or similar toiletry preparations
• A61K 36/00 - Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
• A61P 31/04 - Antibacterial agents
• C07D 487/00 - Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups
• C12N 1/00 - Microorganisms, e.g. protozoaCompositions thereofProcesses of propagating, maintaining or preserving microorganisms or compositions thereofProcesses of preparing or isolating a composition containing a microorganismCulture media therefor
• A61K 36/02 - Algae
• C07D 487/22 - Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups in which the condensed system contains four or more hetero rings
• C12P 17/10 - Nitrogen as only ring hetero atom
• C12R 1/89 - Algae

Abstract

Sphingobiumxenophagumxenophagum as a biological control agent for controlling a pest population, more specifically for treating or preventing a disease in a plant or seed in need thereof.

IPC Classes  ?

• A01N 25/02 - Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of applicationSubstances for reducing the noxious effect of the active ingredients to organisms other than pests containing liquids as carriers, diluents or solvents
• A01N 25/12 - Powders or granules
• A01N 63/20 - BacteriaSubstances produced thereby or obtained therefrom
• A01P 1/00 - DisinfectantsAntimicrobial compounds or mixtures thereof
• A01P 3/00 - Fungicides

Abstract

The present invention relates to a curable isocyanate-free formulation for preparing a polyurethane self-blowing foam comprising at least one multifunctional cyclic carbonate having at least two cyclic carbonate groups at the end of the chain (compound A), at least one multifunctional amine (compound B), at least one masked thiol precursor (compound C) and optionally at least one catalyst (compound D), to a process for preparing said foams, to the thus obtained foams and to the recycling of said foams.

IPC Classes  ?

• C08J 9/02 - Working-up of macromolecular substances to porous or cellular articles or materialsAfter-treatment thereof using blowing gases generated by the reacting monomers or modifying agents during the preparation or modification of macromolecules
• C08G 71/04 - Polyurethanes
• C08J 11/06 - Recovery or working-up of waste materials of polymers without chemical reactions

Abstract

The present invention relates to a compound of formula (I), a tautomer, an enantiomer or a diastereomer thereof, wherein R1, R2, R3 and X have the same meaning as that defined in the claims and the description. The present invention also relates to uses of such compounds as inhibitors of bacterial adhesion and biofilm formation on a surface, methods ex-vivo for preventing bacterial growth in biofilm formation and the use of such compounds in diagnosing or prognosing bacterial infections.

IPC Classes  ?

• A61K 31/7076 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
• A61L 2/00 - Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lensesAccessories therefor
• A61P 31/04 - Antibacterial agents
• A61P 43/00 - Drugs for specific purposes, not provided for in groups

Abstract

Compound of Formula (I) wherein R1is a substituted linear or branched alkyl chain of 1 to 6 carbon atoms; R2is a basic group bearing a positive charge at physiological pH or a precursor thereof, such basic group or precursor thereof being optionally preceded by a linear or branched alkyl chain of 1 to 6 carbon atoms and R2being in the ortho, meta or para position of the ester group on the aryl ring; R3is a halogen with x being an integer between 0 and 4; R4is a halogen with y being an integer between 0 and 3; or a prodrug thereof, and/or a salt thereof, for its use in the treatment of respiratory diseases and compounds of formula I wherein R2 is a basic group bearing a positive charge at physiological pH or a precursor thereof, such basic group or precursor thereof being preceded by a linear or branched alkyl chain of 1 to 6 carbon atoms, preferably of 1 to 2 carbon atoms for use as a medicament.

IPC Classes  ?

• A61K 31/37 - Coumarins, e.g. psoralen
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
• A61P 11/00 - Drugs for disorders of the respiratory system

Abstract

The invention provides a complex comprising at least one proteinaceous agent, an ionic polymer comprising a repetitive unit of formula (I): The invention provides a complex comprising at least one proteinaceous agent, an ionic polymer comprising a repetitive unit of formula (I): The invention provides a complex comprising at least one proteinaceous agent, an ionic polymer comprising a repetitive unit of formula (I): wherein R1 represents a hydrogen atom or a straight or branched chain alkyl group, preferably a straight or branched chain alkyl group comprising from 1 to 6 carbon atoms, for example a methyl group; R2 represents a straight or branched chain alkyl group which is substituted by a group which may have a positive charge at a physiological pH; and optionally a surfactant; a complex for use in a method of medical treatment; a pharmaceutical composition

IPC Classes  ?

• A61K 47/58 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
• A61K 38/38 - Albumins
• A61K 38/28 - Insulins
• A61K 39/21 - Retroviridae, e.g. equine infectious anemia virus
• A61K 9/50 - Microcapsules

Abstract

Module for measuring groundwater flux and optionally solute flux comprising a fluid circuit loop having an abstraction connection and a discharge connection for connecting with a groundwater well respectively at two ends of a column of fluid in said groundwater well; an input line for receiving a volume of tracer, said input line being fluidly connected to the fluid circuit loop upstream from the discharge connection, and comprising an injection pump for injecting said volume of tracer through the discharge connection in the groundwater well; an output line for extracting a volume of fluid, said output line being fluidly connected to the fluid circuit loop downstream from the abstraction connection; a first measuring unit for measuring a tracer concentration in the fluid, said measuring unit being fluidly connectable to the fluid circuit loop between the abstraction connection and the discharge connection. System comprising such module and method for measuring groundwater flux with such module.

IPC Classes  ?

• G01V 9/02 - Determining existence or flow of underground water
• G01F 1/704 - Measuring the volume flow or mass flow of fluid or fluent solid material wherein the fluid passes through a meter in a continuous flow using marked regions or existing inhomogeneities within the fluid stream, e.g. statistically occurring variations in a fluid parameter
• G01P 5/00 - Measuring speed of fluids, e.g. of air streamMeasuring speed of bodies relative to fluids, e.g. of ship, of aircraft
• G01F 1/7086 - Measuring the time taken to traverse a fixed distance using optical detecting arrangements

Abstract

A container system for receiving a liquid sample has a receptacle including a substantially tubular portion for receiving a predetermined volume of the sample. The substantially tubular portion has a first open end and an at least partially openable second end; and a chamber at least partially surrounding the substantially tubular portion. The chamber has an at least partially open upper portion and a closed bottom.

IPC Classes  ?

• B01L 3/00 - Containers or dishes for laboratory use, e.g. laboratory glasswareDroppers

Abstract

The present invention relates to medical imaging, disease monitoring and theranostic approaches in neoplastic diseases of certain anti-CD38 single-domain antibodies (sdAb).

IPC Classes  ?

• A61K 51/10 - Antibodies or immunoglobulinsFragments thereof
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• A61P 35/00 - Antineoplastic agents

Abstract

The present invention relates to a curable isocyanate-free formulation for preparing a polyurethane self-blowing foam comprising at least one multifunctional cyclic carbonate having at least two cyclic carbonate groups at the end of the chain (compound A), at least one multifunctional amine (compound B), water or/and a water source and optionally at least one catalyst (compound D), to a process for preparing said foams and to the thus obtained foams, to a process for recycling the obtained foams and to the thus recycled foams.

IPC Classes  ?

• C08G 71/04 - Polyurethanes
• C08G 18/02 - Polymeric products of isocyanates or isothiocyanates of isocyanates or isothiocyanates only

Goods & Services

Chemistry apparatus and instruments; Chemical reactors; Tubular reactors; Apparatus and instruments for controlling and/or monitoring reactors and/or sensors and/or other equipment of chemistry; Software, in particular for use in the field of chemistry; software for chemical synthesis, production, reaction, purification and/or transformation; Application software for use in the field of chemistry; Collaborative software for use in the field of chemistry; Platform software for use in the field of chemistry. Development and test of chemical methods, including production method, purification methods, transformation methods; Chemical engineering; Scientific laboratory services in the field of chemistry; Hosting services, software as a service, and rental of software; Software as a service [SaaS]; Development of computer platforms; Platform as a Service [PaaS]; Chemical laboratories.

Abstract

The use of an inhibitor of EXT1 expression and/or activity for the production of a biological entity in a cell. Also, the use of a cell having at least depleted EXT1 expression and/or activity for the production of a biological entity. Further, evidence is provided about the role of glycosylation in rapid dynamism of ER shaping and function. In particular, depletion of EXT1 results in a recomposed ER shaping, which could benefit production of recombinant proteins.

IPC Classes  ?

• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• C12N 7/00 - Viruses, e.g. bacteriophagesCompositions thereofPreparation or purification thereof
• C07K 14/705 - ReceptorsCell surface antigensCell surface determinants

Abstract

The invention relates to a process for preparing core-shell particles comprising the steps of (i) providing a dispersion of primary magnetic particles having a mean diameter lower than 200 nm in a solvent; (ii) adding one or more (semi-)metal (oxyhydr)oxide(s) and/or one or more precursor(s) of a (semi-)metal (oxyhydr)oxide to said dispersion; (iii) optionally adding a hydrolysis agent for said one or more precursor(s); (iv) injecting the dispersion in a spray dryer; whereby a (semi-)metal (oxyhydr)oxide shell is formed on the magnetic particles during spray drying. The invention also relates to particles obtainable by said process, to a formulation of said particles in a solvent and to the use of said particles or said formulation for RNA or DNA extraction.

IPC Classes  ?

• B01J 20/32 - Impregnating or coating
• B01J 20/10 - Solid sorbent compositions or filter aid compositionsSorbents for chromatographyProcesses for preparing, regenerating or reactivating thereof comprising inorganic material comprising silica or silicate
• B01J 20/28 - Solid sorbent compositions or filter aid compositionsSorbents for chromatographyProcesses for preparing, regenerating or reactivating thereof characterised by their form or physical properties
• C12N 15/10 - Processes for the isolation, preparation or purification of DNA or RNA
• B01J 20/06 - Solid sorbent compositions or filter aid compositionsSorbents for chromatographyProcesses for preparing, regenerating or reactivating thereof comprising inorganic material comprising oxides or hydroxides of metals not provided for in group

Abstract

An aspect of the invention provides a method for analysing the Duchenne Muscular Dystrophy (DMD) gene in a sample containing genetic material of a subject, wherein the method detects the presence or absence of at least exons 7, 43, 44, 45, 46, 49, 50, 51, 52 and 54 of the DMD gene in the genetic material of the subject, wherein the detection of the presence or absence of the exons comprises multiplex polymerase-based nucleic acid amplification. Another aspect of the invention provides a method for analysing the DMD gene in a sample containing genetic material of a subject, wherein the method detects the presence or absence of at least exons 7, 43, 44, 45, 46, 49, 50, 51, 52 and 54 of the DMD gene in the genetic material of the subject, and wherein the sample is blood. Additional aspects of the invention provide tools applicable in the disclosed methods, such as primers, primer pairs, primer pair sets, oligonucleotide probes and probe sets, as well as compositions and kits containing the same.

IPC Classes  ?

• C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material

Abstract

The invention relates to a computer-assisted method for sizing and then producing a magnetron cavity for an atomic clock, in particular for a hydrogen maser, the cavity being substantially cylindrical and including at least two curved electrodes arranged along an arc of a circle and delimiting a substantially cylindrical space of predetermined radius r, the cavity also including a substantially cylindrical storage bulb of radius rs arranged in said space so that there is a radial gap ei between the at least two electrodes and the storage bulb.

IPC Classes  ?

• G04F 5/14 - Apparatus for producing preselected time intervals for use as timing standards using atomic clocks
• H01S 1/06 - Masers, i.e. devices using stimulated emission of electromagnetic radiation in the microwave range gaseous
• H03L 7/26 - Automatic control of frequency or phaseSynchronisation using energy levels of molecules, atoms, or subatomic particles as a frequency reference

Abstract

The invention relates to an accessory for a plate of a microfluidic experimentation device, comprising a first part and at least one second part, said second part being detachable from said first part, said first part having a plurality of through-holes arranged to enable fluid connection tubes to pass through said first part, said second part having: - at least one recess for at least one microfluidic chip, said recess being made in the thickness of said second part and having a light-passage hole, - a plurality of holes, each hole being arranged to accommodate a fluid reservoir.

IPC Classes  ?

• B01L 9/00 - Supporting devicesHolding devices

Abstract

The invention relates to a cassette intended to contain a microfluidic chip formed from a base made of rigid material and provided with a first wall and from a cover made of rigid material and provided with a second wall, said cassette having an analysis position and an introduction position. The first wall and the second wall each comprise an optically transparent viewing zone, said cassette comprising a series of connecting orifices, each orifice of the series of connecting orifices being designed to be passed through by a connecting tube allowing the passage of a fluid, the second wall also comprising at least one sample introduction orifice.

IPC Classes  ?

• B01L 9/00 - Supporting devicesHolding devices

Abstract

A Cell-free tRNA fragment-based FRET screening and competition assay for inhibitors of human tRNA modification enzymes useful in the prevention or treatment of tRNA modification-related conditions is provided.

IPC Classes  ?

• C12Q 1/6806 - Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
• G01N 33/58 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving labelled substances

Abstract

The present invention relates to a method for detecting an integration pattern of a virus in a host genome. In particular, a method is provided encompassing selective cleavage of circularized DNA fragments carrying viral DNA with an RNA-guided endonuclease and at least one guide RNA or at least one pool of guide RNAs, followed by inverse PCR, in particular inverse long-range PCR, and sequencing. The invention further relates to kits for performing the method and application of the method.

IPC Classes  ?

• C12Q 1/6806 - Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
• C12Q 1/70 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving virus or bacteriophage
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides

Abstract

The present invention relates to the field of droplet microfluidics. It concerns a microfluidic device (1) for manipulating a discrete element (2), for example a droplet. The discrete element (2) comprises a medium (3) and a component (4). The microfluidic device (1) comprises a main microfluidic channel (11), some stopping elements (21, 22, 23) and an attractive mechanism (30) configured to retain, physically and in a releasable way, the component (4) at a given location in the main microfluidic channel (11). The discrete element (2) may be split into a first and second parts in such a way that the component (4) ends in the second parts. The microfluidic device (1) may be used especially for a single- cell analysis.

IPC Classes  ?

• B01L 3/00 - Containers or dishes for laboratory use, e.g. laboratory glasswareDroppers
• G01N 33/48 - Biological material, e.g. blood, urineHaemocytometers

Abstract

The invention provides a complex comprising at least one hydrophobic active agent, an ionic polymer comprising a repetitive unit of formula (I): 5 I wherein R1 represents a hydrogen atom or a straight or branched chain alkyl group, preferably a straight or branched chain alkyl group comprising from 1 to 6 carbon atoms, for example a methyl group; R2 represents a straight or branched chain alkyl group which is substituted by a group which may have a positive charge at a physiological pH wherein the ionic polymer is a homopolymer or a random copolymer, wherein the repetitive unit of formula (I) in a random copolymer comprises (dimethylamino)ethyl 10 methacrylate, wherein the molar proportion of (dimethylamino)ethyl methacrylate repetitive units to the total number of repetitive units in a random copolymer is greater than 50%, and wherein the at least one hydrophobic active agent has a molecular weight of from 100 to 1500 g/mol; a complex for use in a method of medical treatment; a pharmaceutical composition; and a method of preparing a complex or pharmaceutical composition according to the invention which method comprises the steps of: 15 (a) dissolving the hydrophobic active agent and the ionic polymer in one or more non‐aqueous solvents to form the complex wherein the one or more non‐aqueous solvents are miscible with water; and (b) progressively replacing the one or more non‐aqueous solvents with water.

IPC Classes  ?

• A61K 47/58 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
• A61K 9/16 - AgglomeratesGranulatesMicrobeadlets
• A61K 31/121 - Ketones acyclic
• A61K 31/122 - Ketones having the oxygen atom directly attached to a ring, e.g. quinones, vitamin K1, anthralin
• A61K 31/167 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen atom of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
• A61P 43/00 - Drugs for specific purposes, not provided for in groups
• A61K 9/107 - Emulsions

Abstract

The present invention relates to medical imaging, disease monitoring and theranostic approaches in neoplastic diseases of certain anti-CD38 single-domain antibodies (sdAb).

IPC Classes  ?

• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61P 35/00 - Antineoplastic agents
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• A61K 51/10 - Antibodies or immunoglobulinsFragments thereof
• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer

Abstract

The present invention relates to pharmaceutical formulations comprising extracellular vesicles wherein the content of the vesicles comprises microRNA miR-142-3p, methods for producing the pharmaceutical formulations, and uses of the formulations to treat fibro-inflammatory diseases in a subject.

IPC Classes  ?

• A61K 31/713 - Double-stranded nucleic acids or oligonucleotides
• A61P 11/00 - Drugs for disorders of the respiratory system
• A61K 35/15 - Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cellsMyeloid precursor cellsAntigen-presenting cells, e.g. dendritic cells
• A61K 35/33 - Fibroblasts

Abstract

The inventors have found that a an assay using stably transformed human cell lines comprising repetitions of codons sensitive to tRNA modifications upstream of a first luminescence-based reporter gene and repetitions of their synonymous codons upstream of a second luminescence-based reporter gene may be helpful in rapidly identifying modulators of tRNA modifying enzymes.

IPC Classes  ?

• C12N 15/67 - General methods for enhancing the expression
• A61P 35/00 - Antineoplastic agents
• C12Q 1/6897 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters

Abstract

The present invention relates to a composition for promoting plants growth and/or for protecting plants against at least one plant pest and/or one plant disease, said composition comprising simultaneously at least one bacteria of the genus Bacillus producing antifungal lipopeptides, at least one fungi of the genus Trichoderma, and at least one nitrogen mineral source. The present invention also relates to the use of such a composition and to a method for obtaining such a composition. The present invention also relates to a co-culture medium for producing at least in part such a composition.

IPC Classes  ?

• C05C 5/02 - Fertilisers containing other nitrates containing sodium or potassium nitrate
• A01N 63/22 - Bacillus
• A01N 63/38 - Trichoderma
• C05F 11/08 - Organic fertilisers containing added bacterial cultures, mycelia or the like
• C05G 3/60 - Biocides or preservatives, e.g. disinfectants, pesticides or herbicidesPest repellants or attractants

Abstract

The present invention relates to methods for determining the concentration of a carbapenem antibiotic in a biological sample. In particular, the present invention relates to methods for determining the concentration of a carbapenem antibiotic in a biological sample, comprising the steps of: (a) providing a blaOXA-48 class D beta-lactamase (blaOXA-48) or a functionally active variant or fragment thereof; (b) providing a biological sample; (c) contacting the blaOXA-48 or functionally active variant or fragment thereof with the biological sample; and (d) determining the concentration of the carbapenem antibiotic in the biological sample.

IPC Classes  ?

• G01N 33/94 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving narcotics

Abstract

A medical device comprising one or more polyhydroxyurethane (PHU) and a method of manufacturing thereof.Use of the medical device to load and release or graft bioactive molecules, particularly antimicrobial,anti-thrombotic and anticalcification molecules

IPC Classes  ?

• C08G 71/04 - Polyurethanes
• C08G 18/75 - Polyisocyanates or polyisothiocyanates cyclic cycloaliphatic
• C08G 18/48 - Polyethers
• C08G 18/24 - Catalysts containing metal compounds of tin
• C09D 175/04 - Polyurethanes

Abstract

The present invention relates to a curable isocyanate-free formulation for preparing a polyurethane self-blowing foam comprising at least one multifunctional cyclic carbonate having at least two cyclic carbonate groups at the end of the chain (compound A), at least one multifunctional amine (compound B), at least one multifunctional thiol (compound C) and at least one catalyst (compound D), to a process for preparing said foams, to the thus obtained foams and the recycling of said foams.

IPC Classes  ?

• C08G 71/04 - Polyurethanes
• C08J 9/08 - Working-up of macromolecular substances to porous or cellular articles or materialsAfter-treatment thereof using blowing gases generated by a previously added blowing agent by a chemical blowing agent developing carbon dioxide

Abstract

The present invention relates to a curable isocyanate-free formulation for preparing a polyurethane self-blowing foam comprising at least one multifunctional cyclic carbonate having at least two cyclic carbonate groups at the end of the chain (compound A), at least one multifunctional amine (compound B), at least one masked thiol precursor (compound C) and optionally at least one catalyst (compound D), to a process for preparing said foams, to the thus obtained foams and to the recycling of said foams.

IPC Classes  ?

• C08G 71/04 - Polyurethanes
• C08J 9/02 - Working-up of macromolecular substances to porous or cellular articles or materialsAfter-treatment thereof using blowing gases generated by the reacting monomers or modifying agents during the preparation or modification of macromolecules
• C08J 11/06 - Recovery or working-up of waste materials of polymers without chemical reactions

Abstract

The present invention refers to osteomodulin (OMD) protein or fragment of osteomodulin (OMD) protein for use in the prognosis and/or diagnosis of osteoarthritis and/or subchondral bone sclerosis of mammals, preferably human individuals. The present invention further refers to a method for prognosis and/or diagnosis of osteoarthritis and/or subchondral bone sclerosis, comprising the following steps: i) measuring osteomodulin (OMD) protein or a fragment or fragments of osteomodulin (OMD) protein in samples of body fluids of mammalian individuals, preferably human serum samples; ii) judging that decreased levels of osteomodulin (OMD) protein or of said fragment(s) compared to levels in body fluids, preferably serum, of healthy individuals indicate onset of osteoarthritis and/or subchondral bone sclerosis. The present invention also provides an immunological binding partner specifically binding to osteomodulin (OMD) protein or fragment of osteomodulin (OMD) protein for use in the prognosis and/or diagnosis of osteoarthritis and/or subchondral bone sclerosis of mammals, preferably human individuals and a kit comprising said immunological binding partner.

IPC Classes  ?

• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants

Abstract

Disclosed is a symbiotic composition for the treatment or prevention of dysbiosis in piglets during nursing and/or post-weaning, comprising, an effective therapeutic or preventative quantity of (i) Enterococcus faecium, or (ii) Bifidobacterium animalis lactis, or (iii) Clostridium butyricum, or (iv) Bifidobacterium crudilactis, as probiotic and one or more prebiotics, this composition being intended for administration to a pregnant or nursing sow and/or to a nursing and/or post-weaning piglet, in order to promote an anti-inflammatory environment in the intestine of the nursing and/or post-weaning piglet.

IPC Classes  ?

• A23K 10/18 - Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions of live microorganisms
• A61K 35/741 - Probiotics
• A61K 35/742 - Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
• A61K 35/745 - Bifidobacteria
• A23K 20/163 - SugarsPolysaccharides
• A23K 50/30 - Feeding-stuffs specially adapted for particular animals for swine
• A23K 50/60 - Feeding-stuffs specially adapted for particular animals for weanlings
• A23L 33/135 - Bacteria or derivatives thereof, e.g. probiotics
• A23L 33/21 - Addition of substantially indigestible substances, e.g. dietary fibres

Abstract

Disclosed is a symbiotic composition for the treatment or prevention of dysbiosis in piglets during nursing and/or post-weaning, comprising, an effective therapeutic or preventative quantity of (i) Enterococcus faecium, or (ii) Bifidobacterium animalis lactis, or (iii) Clostridium butyricum, or (iv) Bifidobacterium crudilactis, as probiotic and one or more prebiotics, this composition being intended for administration to a pregnant or nursing sow and/or to a nursing and/or post-weaning piglet, in order to promote an anti-inflammatory environment in the intestine of the nursing and/or post-weaning piglet.

IPC Classes  ?

• A23K 10/18 - Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions of live microorganisms
• A23K 20/163 - SugarsPolysaccharides
• A23K 50/30 - Feeding-stuffs specially adapted for particular animals for swine
• A23K 50/60 - Feeding-stuffs specially adapted for particular animals for weanlings
• A23L 33/135 - Bacteria or derivatives thereof, e.g. probiotics
• A23L 33/21 - Addition of substantially indigestible substances, e.g. dietary fibres
• A23L 33/00 - Modifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof
• A61K 31/702 - Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
• A61K 31/733 - Fructosans, e.g. inulin
• A61K 35/741 - Probiotics
• A61K 35/742 - Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
• A61K 35/745 - Bifidobacteria

Abstract

A method of imaging a bacterial infection in a host mammal using Triazolo[4,5-d]pyrimidine derivatives of formula (I): A method of imaging a bacterial infection in a host mammal using Triazolo[4,5-d]pyrimidine derivatives of formula (I): A method of imaging a bacterial infection in a host mammal using Triazolo[4,5-d]pyrimidine derivatives of formula (I): Also disclosed are compositions including the triazolo[4,5-d]pyrimidine derivative.

IPC Classes  ?

• A61K 51/04 - Organic compounds

Abstract

The present invention relates to a method and a composition for eliciting at least one defense mechanism in plants against plant pests and plant diseases.

IPC Classes  ?

• A01N 37/42 - Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids containing within the same carbon skeleton a carboxylic group or a thio-analogue, or a derivative thereof, and a carbon atom having only two bonds to hetero atoms with at the most one bond to halogen, e.g. keto-carboxylic acids
• A01P 21/00 - Plant growth regulators
• A01P 3/00 - Fungicides

Abstract

The invention provides a complex comprising at least one proteinaceous agent, an ionic polymer comprising a repetitive unit of formula (I): wherein R1represents a hydrogen atom or a straight or branched chain alkyl group, preferably a straight or branched chain alkyl group comprising from 1 to 6 carbon atoms, for example a methyl group; R2 represents a straight or branched chain alkyl group which is substituted by a group which may have a positive charge at a physiological pH; and optionally a surfactant; a complex for use in a method of medical treatment; a pharmaceutical composition

IPC Classes  ?

• A61K 47/58 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin

Abstract

The present application relates to an agonist of a human kisspeptin receptor for use in a method of treating a disorder of sexual desire in human females, a method of treating a disorder of sexual desire in a human female patient, comprising administering to said patient a therapeutically effective amount of an agonist of a human kisspeptin receptor and a non-therapeutic method of enhancing libido or inducing sexual arousal in a human female subject, comprising administering to said subject an amount of an agonist of a human kisspeptin receptor sufficient to enhance libido in said subject.

IPC Classes  ?

• A61K 38/09 - Luteinising hormone-releasing hormone [LHRH]Related peptides
• A61P 15/00 - Drugs for genital or sexual disordersContraceptives
• A61K 31/137 - Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine
• A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
• A61K 31/568 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. oestrane, oestradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstane, testosterone
• A61K 31/5685 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. oestrane, oestradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstane, testosterone having an oxo group in position 17, e.g. androsterone
• A61K 38/12 - Cyclic peptides
• A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
• A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
• A61K 31/40 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
• A61K 38/08 - Peptides having 5 to 11 amino acids

Abstract

Disclosed is a container system for receiving a liquid sample, the system comprising a receptacle including a substantially tubular portion for receiving a predetermined volume of the sample, the substantially tubular portion having a first open end and an at least partially openable second end; and a chamber at least partially surrounding the substantially tubular portion, the chamber having an at least partially open upper portion and a closed bottom.

IPC Classes  ?

• B01L 3/00 - Containers or dishes for laboratory use, e.g. laboratory glasswareDroppers

Abstract

In a first aspect, the present invention relates to a composite anode material, comprising: (i) a layer of silicon-carbon (Si/C) composite material comprising silicon-carbon composite particles, and (ii) a graphene oxide (GO) layer covering the layer of silicon-carbon composite material; wherein the silicon-carbon composite particles each comprise a plurality of silicon (Si) particles intermixed with a carbon-based material, and wherein the silicon-carbon composite particles comprise a porous shell surrounding a hollow, the porous shell comprising the plurality of silicon particles intermixed with the carbon-based material.

IPC Classes  ?

• H01M 4/36 - Selection of substances as active materials, active masses, active liquids
• H01M 10/0525 - Rocking-chair batteries, i.e. batteries with lithium insertion or intercalation in both electrodesLithium-ion batteries
• H01M 10/36 - Accumulators not provided for in groups
• H01M 4/134 - Electrodes based on metals, Si or alloys
• H01M 4/133 - Electrodes based on carbonaceous material, e.g. graphite-intercalation compounds or CFx
• H01M 4/62 - Selection of inactive substances as ingredients for active masses, e.g. binders, fillers
• H01M 4/04 - Processes of manufacture in general
• H01M 4/1393 - Processes of manufacture of electrodes based on carbonaceous material, e.g. graphite-intercalation compounds or CFx
• H01M 4/1395 - Processes of manufacture of electrodes based on metals, Si or alloys

Abstract

An inhalable cyclodextrin for use in the treatment and prevention of late phase bronchoconstriction in allergen-induced asthma is disclosed. Further disclosed is the use of a cyclodextrin in the treatment and prevention by inhalation of late phase bronchoconstriction in allergen-induced asthma.

IPC Classes  ?

• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 9/08 - Solutions
• A61K 31/724 - Cyclodextrins
• A61P 37/08 - Antiallergic agents

Abstract

The present invention relates to medical imaging, disease monitoring and theranostic approaches in neoplastic diseases of certain anti-CD38 single-domain antibodies (sdAb).

IPC Classes  ?

• A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
• A61P 35/00 - Antineoplastic agents
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants

Abstract

The invention relates to a process for preparing core-shell particles comprising the steps of (i) providing a dispersion of primary magnetic particles having a mean diameter lower than 200 nm in a solvent; (ii) adding one or more (semi-)metal (oxyhydr)oxide(s) and/or one or more precursor(s) of a (semi-)metal (oxyhydr)oxide to said dispersion; (iii) optionally adding a hydrolysis agent for said one or more precursor(s); (iv) injecting the dispersion in a spray dryer; whereby a (semi-)metal (oxyhydr)oxide shell is formed on the magnetic particles during spray drying. The invention also relates to particles obtainable by said process, to a formulation of said particles in a solvent and to the use of said particles or said formulation for RNA or DNA extraction.

IPC Classes  ?

• B01J 2/06 - Processes or devices for granulating materials, in generalRendering particulate materials free flowing in general, e.g. making them hydrophobic by dividing the liquid material into drops, e.g. by spraying, and solidifying the drops in a liquid medium
• B01J 20/06 - Solid sorbent compositions or filter aid compositionsSorbents for chromatographyProcesses for preparing, regenerating or reactivating thereof comprising inorganic material comprising oxides or hydroxides of metals not provided for in group
• B01J 20/10 - Solid sorbent compositions or filter aid compositionsSorbents for chromatographyProcesses for preparing, regenerating or reactivating thereof comprising inorganic material comprising silica or silicate
• B01J 20/28 - Solid sorbent compositions or filter aid compositionsSorbents for chromatographyProcesses for preparing, regenerating or reactivating thereof characterised by their form or physical properties
• B01J 20/32 - Impregnating or coating
• C12N 15/10 - Processes for the isolation, preparation or purification of DNA or RNA
• C12Q 1/6806 - Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
• B01J 20/08 - Solid sorbent compositions or filter aid compositionsSorbents for chromatographyProcesses for preparing, regenerating or reactivating thereof comprising inorganic material comprising oxides or hydroxides of metals not provided for in group comprising aluminium oxide or hydroxideSolid sorbent compositions or filter aid compositionsSorbents for chromatographyProcesses for preparing, regenerating or reactivating thereof comprising inorganic material comprising oxides or hydroxides of metals not provided for in group comprising bauxite

Abstract

DMDDMDDMD gene in a sample containing genetic material of a subject, wherein the method detects the presence or absence of at least exons 7, 43, 44, 45, 46, 49, 50, 51, 52 and 54 of the DMD gene in the genetic material of the subject, and wherein the sample is blood. Additional aspects of the invention provide tools applicable in the disclosed methods, such as primers, primer pairs, primer pair sets, oligonucleotide probes and probe sets, as well as compositions and kits containing the same.

IPC Classes  ?

• C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material

Abstract

New pyrimidine derivatives together with a membrane penetrating agent, optionally with a detectable isotope and pharmaceutical composition for use in treatment or prevention of Gram-negative bacterial infection in a host mammal in need of such treatment or prevention and use as inhibitors of Gram-negative biofilm formation on a surface of biomaterial or medical device, particularly of cardiovascular device such as prosthetic heart valve or pacemakers. New pyrimidine derivatives together with a membrane penetrating agent; for use as radiotracer in diagnosing or prognosing Gram-negative bacterial infection in a host mammal.

IPC Classes  ?

• A61K 31/52 - Purines, e.g. adenine
• A61K 38/12 - Cyclic peptides
• A61P 31/04 - Antibacterial agents
• A61K 51/04 - Organic compounds
• A01N 43/90 - Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having two or more relevant hetero rings, condensed among themselves or with a common carbocyclic ring system
• A01N 43/713 - Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with four or more nitrogen atoms as the only ring hetero atoms

Abstract

The present invention relates to the use of an inhibitor of EXT1 expression and/or activity for the production of a biological entity in a cell. The invention also relates to the use of a cell having at least depleted EXT1 expression and/or activity for the production of a biological entity. The inventors provide herein evidences about the role of glycosylation in rapid dynamism of ER shaping and function. In particular, depletion of EXT1 results in a recomposed ER shaping, which could benefit production of recombinant proteins.

IPC Classes  ?

• A61K 31/7088 - Compounds having three or more nucleosides or nucleotides
• C12N 15/11 - DNA or RNA fragmentsModified forms thereof

Abstract

Fat tissue removal device comprising a cannula (100) comprising an evacuation tube (150) for connecting an evacuation system, a blunt cap (110) provided at a distal end of the cannula (100), and a rotatable shaft (130) comprising a cutting element (120) attached to the rotatable shaft, said rotatable shaft further being configured to be connectable to a driving device, the blunt cap (110) comprising a grinding chamber (160) for grinding fat tissue with the cutting element (120), an assembly comprising such device, a kit of parts for the removal of fat tissue, and a method for the removal of fat tissue with such device.

IPC Classes  ?

• A61M 1/00 - Suction or pumping devices for medical purposesDevices for carrying-off, for treatment of, or for carrying-over, body-liquidsDrainage systems
• A61B 17/32 - Surgical cutting instruments

Abstract

The present invention relates to the use of an inhibitor of EXT1 expression and/or activity for the production of a biological entity in a cell. The invention also relates to the use of a cell having at least depleted EXT1 expression and/or activity for the production of a biological entity. The inventors provide herein evidences about the role of glycosylation in rapid dynamism of ER shaping and function. In particular, depletion of EXT1 results in a recomposed ER shaping, which could benefit production of recombinant proteins.

IPC Classes  ?

• A61K 31/7088 - Compounds having three or more nucleosides or nucleotides
• C12N 15/11 - DNA or RNA fragmentsModified forms thereof

Abstract

The present invention relates to a herbicidal composition comprising at least one essential oil as an active compound, at least one surfactant and at least one oily substance, said composition being under the form of an emulsion.

IPC Classes  ?

• A01N 25/04 - Dispersions or gels
• A01N 25/30 - Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of applicationSubstances for reducing the noxious effect of the active ingredients to organisms other than pests characterised by the surfactants
• A01N 65/44 - Poaceae or Gramineae [Grass family], e.g. bamboo, lemon grass or citronella grass
• A01N 65/24 - Lauraceae [Laurel family], e.g. laurel, avocado, sassafras, cinnamon or camphor

Abstract

A microfluidic module for co-encapsulation in droplets of two populations of particles may include first and second modules for sorting the two populations. The modules may have their first outlets including first obstructive valves configured to at least partially obstruct the first outlets. The first outlets may be fluidly connected to a fusion module, including a fusion module means for merging at least one droplet from the first droplet population and at least one droplet from the second droplet population into a merged droplet comprising the two population of particles, and a control unit for controlling the first obstructive valves from information originating from a first and second module detection portion located upstream of the first outlets.

IPC Classes  ?

• B01L 1/00 - EnclosuresChambers
• B01F 23/41 - Emulsifying
• B01F 33/301 - Micromixers using specific means for arranging the streams to be mixed, e.g. channel geometries or dispositions
• B01F 33/302 - Micromixers the materials to be mixed flowing in the form of droplets
• B01F 35/214 - Measuring characterised by the means for measuring
• B01F 35/221 - Control or regulation of operational parameters, e.g. level of material in the mixer, temperature or pressure
• B01F 35/71 - Feed mechanisms
• B01J 13/08 - Simple coacervation, i.e. addition of highly hydrophilic material
• B01F 101/23 - Mixing of laboratory samples e.g. in preparation of analysing or testing properties of materials

Abstract

The present invention relates to a method for detecting an integration pattern of a virus, such as human papilloma virus (HPV) in a host genome. In particular, a method is provided encompassing selective cleavage of circularized DNA fragments carrying viral DNA with an RNA-guided endonuclease and at least one guide RNA or at least one pool of guide RNAs, followed by inverse PCR, in particular inverse long-range PCR, and sequencing ("Pooled CRISPR Inverse PCR sequencing (PCIP-seq)". The invention further relates to kits for performing the method and application of the method.

IPC Classes  ?

• C12Q 1/6806 - Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
• C12Q 1/70 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving virus or bacteriophage
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides

Abstract

Pyrimidine derivatives of formula (I): optionally with a detectable isotope, pharmaceutical composition and method of preparation thereof. Pyrimidine derivatives for use in treatment or prevention of bacterial infection in a host mammal in need of such treatment or prevention and use as inhibitors of biofilm formation on a surface of biomaterial or medical device, particularly of cardiovascular device such as prosthetic heart valve or pacemakers. Pyrimidine derivatives for use as radiotracer in diagnosing or prognosing bacterial infection in a host mammal.

IPC Classes  ?

• C07D 473/40 - Heterocyclic compounds containing purine ring systems with halogen atoms or perhalogeno-alkyl radicals directly attached in position 2 or 6
• A61K 9/00 - Medicinal preparations characterised by special physical form
• C07D 473/28 - Oxygen atom

Abstract

The present invention relates to methods for determining the concentration of a carbapenem antibiotic in a biological sample. In particular, the present invention relates to methods for determining the concentration of a carbapenem antibiotic in a biological sample, comprising the steps of: (a) providing a blaOXA-48 class D beta-lactamase (blaOXA-48) or a functionally active variant or fragment thereof; (b) providing a biological sample; (c) contacting the blaOXA-48 or functionally active variant or fragment thereof with the biological sample; and (d) determining the concentration of the carbapenem antibiotic in the biological sample.

IPC Classes  ?

• C12Q 1/34 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving hydrolase
• C12N 9/78 - Hydrolases (3.) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
• C12Q 1/18 - Testing for antimicrobial activity of a material
• G01N 33/94 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving narcotics

Abstract

The present invention relates to methods for determining the concentration of a carbapenem antibiotic in a biological sample. In particular, the present invention relates to methods for determining the concentration of a carbapenem antibiotic in a biological sample, comprising the steps of: (a) providing a blaOXA-48 class D beta-lactamase (blaOXA-48) or a functionally active variant or fragment thereof; (b) providing a biological sample; (c) contacting the blaOXA-48 or functionally active variant or fragment thereof with the biological sample; and (d) determining the concentration of the carbapenem antibiotic in the biological sample.

IPC Classes  ?

• C12Q 1/18 - Testing for antimicrobial activity of a material
• G01N 33/94 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving narcotics

Abstract

Triazolo[4,5-d]pyrimidine derivatives of formula (I) for use in prognosis and/or diagnosis of bacterial infection in a host mammal and method of imaging thereof. Formula (I) wherein R1 is C3-5 alkyl optionally substituted by one or more halogen atoms; R2 is a phenyl group, optionally substituted by one or more halogen atoms; R3 and R4 are each hydroxyl; R is XOH, wherein X is CH2, OCH2CH2, or a bond; or a pharmaceutical acceptable salt or solvate thereof, or a solvate of such a salt provided that when X is CH2 or a bond, R1 is not propyl; when X is CH2 and R1 CH2CH2CF3, butyl or pentyl, the phenyl group at R2 must be substituted by fluorine; when X is OCH2CH2 and R1 is propyl, the phenyl group at R2 must be substituted by fluorine.

IPC Classes  ?

• A61K 49/00 - Preparations for testing in vivo
• A61K 51/04 - Organic compounds
• C07D 487/04 - Ortho-condensed systems

Abstract

Triazolo[4,5-d]pyrimidine derivatives of formula (I) for use in prognosis and/or diagnosis of bacterial infection in a host mammal and method of imaging thereof. Formula (I) wherein R13-53-5 alkyl optionally substituted by one or more halogen atoms; R2is a phenyl group, optionally substituted by one or more halogen atoms; R3and R422222 or a bond, R122 and R12233, butyl or pentyl, the phenyl group at R2222 and R1 is propyl, the phenyl group at R2 must be substituted by fluorine.

IPC Classes  ?

• A61K 51/04 - Organic compounds
• A61K 101/02 - Halogens
• C07D 487/04 - Ortho-condensed systems

Abstract

The present invention relates to pharmaceutical formulations comprising extracellular vesicles wherein the content of the vesicles comprises microRNA miR-142-3p, methods for producing the pharmaceutical formulations, and uses of the formulations to treat fibro-inflammatory diseases in a subject.

IPC Classes  ?

• A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• A61K 9/51 - Nanocapsules
• A61K 35/12 - Materials from mammalsCompositions comprising non-specified tissues or cellsCompositions comprising non-embryonic stem cellsGenetically modified cells
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
• C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
• C12N 15/10 - Processes for the isolation, preparation or purification of DNA or RNA
• C12N 15/63 - Introduction of foreign genetic material using vectorsVectorsUse of hosts thereforRegulation of expression
• C12N 15/88 - Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using liposome vesicle

Abstract

The present invention relates to pharmaceutical formulations comprising extracellular vesicles wherein the content of the vesicles comprises microRNA miR-142-3p, methods for producing the pharmaceutical formulations, and uses of the formulations to treat fibro-inflammatory diseases in a subject.

IPC Classes  ?

• C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material

Abstract

The present invention relates to a curable isocyanate-free formulation for preparing a polyurethane self-blowing foam comprising at least one multifunctional cyclic carbonate having at least two cyclic carbonate groups at the end of the chain (compound A), at least one multifunctional amine (compound B), at least one multifunctional thiol (compound C) and at least one catalyst (compound D), to a process for preparing said foams and to the thus obtained foams.

IPC Classes  ?

• C08G 71/04 - Polyurethanes
• C08J 9/02 - Working-up of macromolecular substances to porous or cellular articles or materialsAfter-treatment thereof using blowing gases generated by the reacting monomers or modifying agents during the preparation or modification of macromolecules
• C08G 101/00 - Manufacture of cellular products

Abstract

The present invention relates to a herbicidal composition comprising at least one phenolic active compound being myricitrin. The invention also relates to the use of such a herbicidal composition.

IPC Classes  ?

• A01N 43/42 - Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom six-membered rings condensed with carbocyclic rings
• A01N 37/10 - Aromatic or araliphatic carboxylic acids, or thio-analogues thereofDerivatives thereof

Abstract

In vitro methods for diagnosing, prognosing and/or monitoring and treating neutrophilic or eosinophilic airway inflammation in a subject, including determining the amount of one or more volatile organic compounds (VOCs) in exhaled breath from said subject. The invention also provides devices for use in said methods.

IPC Classes  ?

• A61B 5/08 - Measuring devices for evaluating the respiratory organs
• A61B 5/097 - Devices for facilitating collection of breath or for directing breath into or through measuring devices
• G01N 30/72 - Mass spectrometers
• G01N 33/497 - Physical analysis of biological material of gaseous biological material, e.g. breath

Abstract

New pyrimidine derivatives together with a membrane penetrating agent, optionally with a detectable isotope and pharmaceutical composition for use in treatment or prevention of Gram-negative bacterial infection in a host mammal in need of such treatment or prevention and use as inhibitors of Gram-negative biofilm formation on a surface of biomaterial or medical device, particularly of cardiovascular device such as prosthetic heart valve or pacemakers. New pyrimidine derivatives together with a membrane penetrating agent; for use as radiotracer in diagnosing or prognosing Gram-negative bacterial infection in a host mammal.

IPC Classes  ?

• A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
• A61K 31/52 - Purines, e.g. adenine
• A61P 31/02 - Local antiseptics
• A61P 31/04 - Antibacterial agents
• C07D 473/24 - Heterocyclic compounds containing purine ring systems with oxygen, sulfur, or nitrogen atoms directly attached in positions 2 and 6 one nitrogen and one sulfur atom
• C07D 487/04 - Ortho-condensed systems

Abstract

New pyrimidine derivatives together with a membrane penetrating agent, optionally with a detectable isotope and pharmaceutical composition for use in treatment or prevention of Gram-negative bacterial infection in a host mammal in need of such treatment or prevention and use as inhibitors of Gram-negative biofilm formation on a surface of biomaterial or medical device, particularly of cardiovascular device such as prosthetic heart valve or pacemakers. New pyrimidine derivatives together with a membrane penetrating agent; for use as radiotracer in diagnosing or prognosing Gram-negative bacterial infection in a host mammal.

IPC Classes  ?

• A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
• A61K 31/52 - Purines, e.g. adenine
• A61P 31/04 - Antibacterial agents
• A61P 31/02 - Local antiseptics
• C07D 473/24 - Heterocyclic compounds containing purine ring systems with oxygen, sulfur, or nitrogen atoms directly attached in positions 2 and 6 one nitrogen and one sulfur atom
• C07D 487/04 - Ortho-condensed systems

Abstract

The present application relates to an agonist of a human kisspeptin receptor for use in a method of treating a disorder of sexual desire in human females, a method of treating a disorder of sexual desire in a human female patient, comprising administering to said patient a therapeutically effective amount of an agonist of a human kisspeptin receptor and a non-therapeutic method of enhancing libido or inducing sexual arousal in a human female subject, comprising administering to said subject an amount of an agonist of a human kisspeptin receptor sufficient to enhance libido in said subject.

IPC Classes  ?

• A61K 38/04 - Peptides having up to 20 amino acids in a fully defined sequenceDerivatives thereof
• A61P 15/00 - Drugs for genital or sexual disordersContraceptives

Abstract

A polyvinyl alcohol has a number-average molecular weight (Mn) from 4,400 to 440,000, a molecular weight distribution (Mw/Mn) from 1.05 to 1.70, a degree of saponification from 80 to 99.99 mol %, wherein the polyvinyl alcohol contains an end group represented by a formula (I) below, and a molar ratio (X) of the end group based on total monomer units and the number-average molecular weight (Mn) satisfy a formula (1) below. Such a polyvinyl alcohol has a narrow molecular weight distribution and a high number-average molecular weight with hue good. X·Mn/44≥0.5  (1)

IPC Classes  ?

• C08F 16/06 - Polyvinyl alcohol
• C08F 2/38 - Polymerisation using regulators, e.g. chain terminating agents
• C08F 8/12 - Hydrolysis

Abstract

In a first aspect, the present invention relates to a composite anode material, comprising: (i) a layer of silicon-carbon (Si/C) composite material comprising silicon-carbon composite particles, and (ii) a graphene oxide (GO) layer covering the layer of silicon-carbon composite material; wherein the silicon-carbon composite particles each comprise a plurality of silicon (Si) particles intermixed with a carbon-based material, and wherein the silicon-carbon composite particles comprise a porous shell surrounding a hollow, the porous shell comprising the plurality of silicon particles intermixed with the carbon-based material.

IPC Classes  ?

• H01M 4/04 - Processes of manufacture in general
• H01M 4/134 - Electrodes based on metals, Si or alloys
• H01M 4/1395 - Processes of manufacture of electrodes based on metals, Si or alloys
• H01M 4/62 - Selection of inactive substances as ingredients for active masses, e.g. binders, fillers
• H01M 10/0525 - Rocking-chair batteries, i.e. batteries with lithium insertion or intercalation in both electrodesLithium-ion batteries
• H01M 4/02 - Electrodes composed of, or comprising, active material

Abstract

In a first aspect, the present invention relates to a composite anode material, comprising: (i) a layer of silicon-carbon (Si/C) composite material comprising silicon-carbon composite particles, and (ii) a graphene oxide (GO) layer covering the layer of silicon-carbon composite material; wherein the silicon-carbon composite particles each comprise a plurality of silicon (Si) particles intermixed with a carbon-based material, and wherein the silicon-carbon composite particles comprise a porous shell surrounding a hollow, the porous shell comprising the plurality of silicon particles intermixed with the carbon-based material.

IPC Classes  ?

• H01M 4/04 - Processes of manufacture in general
• H01M 4/134 - Electrodes based on metals, Si or alloys
• H01M 4/1395 - Processes of manufacture of electrodes based on metals, Si or alloys
• H01M 10/0525 - Rocking-chair batteries, i.e. batteries with lithium insertion or intercalation in both electrodesLithium-ion batteries
• H01M 4/02 - Electrodes composed of, or comprising, active material
• H01M 4/62 - Selection of inactive substances as ingredients for active masses, e.g. binders, fillers

Abstract

The invention is related to an inducible promoter for improved and regulated gene expression, useful in synthetic biology and metabolic engineering. In particular, the present invention relates to a nucleotide sequence comprising the regulatory regions of an erythritol- and erythrulose-inducible promoter in yeast and uses thereof in an expression system thus allowing an improved and regulated gene expression and production of gene product.

IPC Classes  ?

• C12N 15/81 - Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
• C07K 14/39 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from fungi from yeasts
• C12N 9/12 - Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)

Abstract

Microfluidic module (100) for co-encapsulation in droplets of two populations of particles, comprising a first (1) and a second (2) modules for sorting said two populations, said modules (1, 2) having their first outlets (12, 22) comprising first obstructive valves (121, 221) configured to at least partially obstruct said first outlets (12, 22), said first outlets (12, 22) being fluidly connected to: - a fusion module (3) comprising: • a fusion module means (30) for merging at least one droplet from the first droplet population and at least one droplet from the second droplet population into a merged droplet comprising said two population of particles, - a control unit (4) for controlling: • said first obstructive valves (121, 221) from information originating from a first (19) and second (29) module detection portion located upstream of said first outlets (12, 22).

IPC Classes  ?

• B01J 13/04 - Making microcapsules or microballoons by physical processes, e.g. drying, spraying

Abstract

Microfluidic module (100) for co-encapsulation in droplets of two populations of particles, comprising a first (1) and a second (2) modules for sorting said two populations, said modules (1, 2) having their first outlets (12, 22) comprising first obstructive valves (121, 221) configured to at least partially obstruct said first outlets (12, 22), said first outlets (12, 22) being fluidly connected to: - a fusion module (3) comprising: a fusion module means (30) for merging at least one droplet from the first droplet population and at least one droplet from the second droplet population into a merged droplet comprising said two population of particles, - a control unit (4) for controlling: said first obstructive valves (121, 221) from information originating from a first (19) and second (29) module detection portion located upstream of said first outlets (12, 22).

IPC Classes  ?

• B01J 13/04 - Making microcapsules or microballoons by physical processes, e.g. drying, spraying

Abstract

A composition comprises: an at least partially hydrolysed polyvinyl acetate component having an hydrolysation degree of at least 5%; a polyalkylene glycol component having a number average molecular mass Mn lower than 9000 g/mol and consisting of one or more substances selected from the group consisting of polyethylene glycol, polypropylene glycol, copolymers of ethylene glycol and propylene glycol, and their derivatives; a positive or negative electrode active component; and a conductive component; wherein the mass ratio between the at least partially hydrolysed polyvinyl acetate component and the positive or negative electrode active component equals at least 0.12 and at most 0.30, and wherein the mass ratio between the polyalkylene glycol component and the positive or negative electrode active component equals at least 0.012 and at most 0.10.

IPC Classes  ?

• H01M 4/04 - Processes of manufacture in general
• H01M 4/62 - Selection of inactive substances as ingredients for active masses, e.g. binders, fillers
• H01M 10/052 - Li-accumulators
• H01M 8/0223 - Composites
• H01M 10/05 - Accumulators with non-aqueous electrolyte
• H01M 4/13 - Electrodes for accumulators with non-aqueous electrolyte, e.g. for lithium-accumulatorsProcesses of manufacture thereof
• H01M 4/02 - Electrodes composed of, or comprising, active material

Abstract

This apparatus (30) for the production of microalgae comprises a vessel (1) intended to receive a culture medium of the microalgae, and a lighting device (6) intended to be positioned in the vessel inside the culture medium. The lighting device (6) is configured to emit light at least in a range of wavelengths useful for the photosynthesis of the microalgae. The apparatus comprises a control system (15) for automatically controlling a power supply of the lighting device (6) so as to adjust the output light intensity of the lighting device (6) according to the concentration of microalgae in the vessel (1).

IPC Classes  ?

• C12M 1/00 - Apparatus for enzymology or microbiology

Abstract

This apparatus (30) for the production of microalgae comprises a vessel (1) intended to receive a culture medium of the microalgae, and a lighting device (6) intended to be positioned in the vessel inside the culture medium. The lighting device (6) is configured to emit light at least in a range of wavelengths useful for the photosynthesis of the microalgae. The apparatus comprises a control system (15) for automatically controlling a power supply of the lighting device (6) so as to adjust the output light intensity of the lighting device (6) according to the concentration of microalgae in the vessel (1).

IPC Classes  ?

• C12M 1/00 - Apparatus for enzymology or microbiology

Abstract

Herbicidal composition comprising at least one essential oil The present invention relates to a herbicidal composition comprising at least one essential oil as an active compound, at least one surfactant and at least one oily substance, said composition being under the form of an emulsion.

IPC Classes  ?

• A01N 25/04 - Dispersions or gels
• A01N 65/12 - Asteraceae or Compositae [Aster or Sunflower family], e.g. daisy, pyrethrum, artichoke, lettuce, sunflower, wormwood or tarragon
• A01N 65/24 - Lauraceae [Laurel family], e.g. laurel, avocado, sassafras, cinnamon or camphor
• A01N 65/28 - Myrtaceae [Myrtle family], e.g. teatree or clove
• A01N 65/44 - Poaceae or Gramineae [Grass family], e.g. bamboo, lemon grass or citronella grass
• A01N 25/30 - Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of applicationSubstances for reducing the noxious effect of the active ingredients to organisms other than pests characterised by the surfactants
• A01P 13/00 - HerbicidesAlgicides

Abstract

A computer-implemented method for training a neural network for classifying image data and a related computer program product are disclosed. A labelled input data set comprising a plurality of labelled image data samples is provided together with a neural network. The neural network comprises an input layer, at least one intermediate layer, and an output layer having one channel per label class. Each channel comprises a plurality of neurons of the output layer and is generating a multidimensional feature vector in response to an image data sample presented to the input layer of the neural network. Furthermore, the input layer of a decoder network for reconstructing image data samples at its output is connected to the output layer of the neural network. A classifier predicts class labels as the labels of those channels for which a normed distance of its corresponding feature vector relative to a pre-determined reference point is smallest. A loss function for the neural network is suitable for steering, for each channel, the feature vectors onto which image data samples of the associated class are mapped, into a convex region around the pre-determined reference point.

IPC Classes  ?

• G06K 9/46 - Extraction of features or characteristics of the image
• G06K 9/62 - Methods or arrangements for recognition using electronic means

Abstract

Herbicidal composition comprising at least one essential oil The present invention relates to a herbicidal composition comprising at least one essential oil as an active compound, at least one surfactant and at least one oily substance, said composition being under the form of an emulsion.

IPC Classes  ?

• A01N 25/04 - Dispersions or gels
• A01N 25/30 - Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of applicationSubstances for reducing the noxious effect of the active ingredients to organisms other than pests characterised by the surfactants
• A01N 65/24 - Lauraceae [Laurel family], e.g. laurel, avocado, sassafras, cinnamon or camphor
• A01N 65/12 - Asteraceae or Compositae [Aster or Sunflower family], e.g. daisy, pyrethrum, artichoke, lettuce, sunflower, wormwood or tarragon
• A01N 65/44 - Poaceae or Gramineae [Grass family], e.g. bamboo, lemon grass or citronella grass
• A01N 65/28 - Myrtaceae [Myrtle family], e.g. teatree or clove
• A01P 13/00 - HerbicidesAlgicides

Abstract

Herbicidal composition comprising at least one phenolic active compound The present invention relates to a herbicidal composition comprising at least one phenolic active compound being myricitrin. The invention also relates to the use of such a herbicidal composition.

IPC Classes  ?

• A01P 13/00 - HerbicidesAlgicides
• A01N 43/16 - Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one or more oxygen or sulfur atoms as the only ring hetero atom with one hetero atom six-membered rings with oxygen as the ring hetero atom

Abstract

A process to prepare an electrode for an electrochemical storage device by spraying an aqueous slurry composition comprising water, xanthan gum, a source of conducting carbon particles and an active material on an electrode base. The slurry may be made by first mixing solid xanthan gum with the conducting carbon particles and the active material and secondly adding water to the resulting mixture. Alternatively the slurry is obtained by mixing solid xanthan gum with a carbon-based active material and adding water to the resulting mixture obtained.

IPC Classes  ?

• H01M 4/04 - Processes of manufacture in general
• H01M 4/36 - Selection of substances as active materials, active masses, active liquids
• H01M 4/1315 - Electrodes based on mixed oxides or hydroxides, or on mixtures of oxides or hydroxides, e.g. LiCoOx containing halogen atoms, e.g. LiCoOxFy
• H01M 4/133 - Electrodes based on carbonaceous material, e.g. graphite-intercalation compounds or CFx
• H01M 4/1391 - Processes of manufacture of electrodes based on mixed oxides or hydroxides, or on mixtures of oxides or hydroxides, e.g. LiCoOx
• H01M 4/1393 - Processes of manufacture of electrodes based on carbonaceous material, e.g. graphite-intercalation compounds or CFx
• H01M 4/525 - Selection of substances as active materials, active masses, active liquids of inorganic oxides or hydroxides of nickel, cobalt or iron of mixed oxides or hydroxides containing iron, cobalt or nickel for inserting or intercalating light metals, e.g. LiNiO2, LiCoO2 or LiCoOxFy
• H01M 4/62 - Selection of inactive substances as ingredients for active masses, e.g. binders, fillers
• H01M 4/66 - Selection of materials
• H01M 4/88 - Processes of manufacture
• H01M 10/54 - Reclaiming serviceable parts of waste accumulators
• H01M 4/58 - Selection of substances as active materials, active masses, active liquids of inorganic compounds other than oxides or hydroxides, e.g. sulfides, selenides, tellurides, halogenides or LiCoFySelection of substances as active materials, active masses, active liquids of polyanionic structures, e.g. phosphates, silicates or borates
• H01M 4/587 - Carbonaceous material, e.g. graphite-intercalation compounds or CFx for inserting or intercalating light metals
• H01M 4/1397 - Processes of manufacture of electrodes based on inorganic compounds other than oxides or hydroxides, e.g. sulfides, selenides, tellurides, halogenides or LiCoFy
• H01M 4/485 - Selection of substances as active materials, active masses, active liquids of inorganic oxides or hydroxides of mixed oxides or hydroxides for inserting or intercalating light metals, e.g. LiTi2O4 or LiTi2OxFy
• H01M 4/136 - Electrodes based on inorganic compounds other than oxides or hydroxides, e.g. sulfides, selenides, tellurides, halogenides or LiCoFy
• H01M 4/1395 - Processes of manufacture of electrodes based on metals, Si or alloys
• H01M 4/38 - Selection of substances as active materials, active masses, active liquids of elements or alloys
• H01M 4/131 - Electrodes based on mixed oxides or hydroxides, or on mixtures of oxides or hydroxides, e.g. LiCoOx

Abstract

An in-vitro method for early diagnosing or prediction of immune-mediated inflammatory diseases, comprising: —obtaining a sample from a subject; —quantifying simultaneously by one LC/MS-MS analysis of said sample, a presence of V65 vitronectin fragment or fragment, variant or degradation product thereof; and a presence of a complement C3f or fragment or variant or degradation products thereof.

IPC Classes  ?

• G01N 33/564 - ImmunoassayBiospecific binding assayMaterials therefor for pre-existing immune complex or autoimmune disease
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids

Abstract

The present application relates to methods for determining the proportion or quantity of DNA contributed by individual animals to a volume of milk collected from a plurality of individual animals, wherein the method employs allele sampling for DNA sequence polymorphisms in DNA extracted from a sample of the volume of milk by shallow whole genome sequencing (SWGS). The present methods are useful for example in detecting mastitis or subclinical mastitis in animals contributing milk to the volume of milk.

IPC Classes  ?

• C12Q 1/6869 - Methods for sequencing
• C12Q 1/6888 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms

Abstract

The present application relates to methods for determining the proportion or quantity of DNA contributed by individual animals to a volume of milk collected from a plurality of individual animals, wherein the method employs allele sampling for DNA sequence polymorphisms in DNA extracted from a sample of the volume of milk by shallow whole genome sequencing (SWGS). The present methods are useful for example in detecting mastitis or subclinical mastitis in animals contributing milk to the volume of milk.

IPC Classes  ?

• C12Q 1/6869 - Methods for sequencing
• C12Q 1/6888 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms

Abstract

The present invention relates to a herbicidal composition comprising at least one phenolic active compound being myricitrin. The invention also relates to the use of such a herbicidal composition.

IPC Classes  ?

• A01N 43/16 - Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one or more oxygen or sulfur atoms as the only ring hetero atom with one hetero atom six-membered rings with oxygen as the ring hetero atom
• A01N 25/30 - Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of applicationSubstances for reducing the noxious effect of the active ingredients to organisms other than pests characterised by the surfactants
• A01P 13/00 - HerbicidesAlgicides

Abstract

A process to prepare an electrode for an electrochemical storage device by spraying an aqueous slurry composition comprising water, xanthan gum, a source of conducting carbon particles and an active material on an electrode base. The slurry may be made by first mixing solid xanthan gum with the conducting carbon particles and the active material and secondly adding water to the resulting mixture. Alternatively the slurry is obtained by mixing solid xanthan gum with a carbon-based active material and adding water to the resulting mixture obtained.

IPC Classes  ?

• H01M 4/04 - Processes of manufacture in general
• H01M 4/36 - Selection of substances as active materials, active masses, active liquids
• H01M 4/1315 - Electrodes based on mixed oxides or hydroxides, or on mixtures of oxides or hydroxides, e.g. LiCoOx containing halogen atoms, e.g. LiCoOxFy
• H01M 4/133 - Electrodes based on carbonaceous material, e.g. graphite-intercalation compounds or CFx
• H01M 4/1391 - Processes of manufacture of electrodes based on mixed oxides or hydroxides, or on mixtures of oxides or hydroxides, e.g. LiCoOx
• H01M 4/1393 - Processes of manufacture of electrodes based on carbonaceous material, e.g. graphite-intercalation compounds or CFx
• H01M 4/525 - Selection of substances as active materials, active masses, active liquids of inorganic oxides or hydroxides of nickel, cobalt or iron of mixed oxides or hydroxides containing iron, cobalt or nickel for inserting or intercalating light metals, e.g. LiNiO2, LiCoO2 or LiCoOxFy
• H01M 4/62 - Selection of inactive substances as ingredients for active masses, e.g. binders, fillers
• H01M 4/66 - Selection of materials
• H01M 4/88 - Processes of manufacture
• H01M 10/54 - Reclaiming serviceable parts of waste accumulators
• H01M 4/58 - Selection of substances as active materials, active masses, active liquids of inorganic compounds other than oxides or hydroxides, e.g. sulfides, selenides, tellurides, halogenides or LiCoFySelection of substances as active materials, active masses, active liquids of polyanionic structures, e.g. phosphates, silicates or borates
• H01M 4/587 - Carbonaceous material, e.g. graphite-intercalation compounds or CFx for inserting or intercalating light metals
• H01M 4/1397 - Processes of manufacture of electrodes based on inorganic compounds other than oxides or hydroxides, e.g. sulfides, selenides, tellurides, halogenides or LiCoFy
• H01M 4/485 - Selection of substances as active materials, active masses, active liquids of inorganic oxides or hydroxides of mixed oxides or hydroxides for inserting or intercalating light metals, e.g. LiTi2O4 or LiTi2OxFy
• H01M 4/136 - Electrodes based on inorganic compounds other than oxides or hydroxides, e.g. sulfides, selenides, tellurides, halogenides or LiCoFy
• H01M 4/1395 - Processes of manufacture of electrodes based on metals, Si or alloys
• H01M 4/38 - Selection of substances as active materials, active masses, active liquids of elements or alloys
• H01M 4/131 - Electrodes based on mixed oxides or hydroxides, or on mixtures of oxides or hydroxides, e.g. LiCoOx

Abstract

The present invention relates to a herbicidal composition comprising at least one phenolic active compound being myricitrin. The invention also relates to the use of such a herbicidal composition.

IPC Classes  ?

• A01P 13/00 - HerbicidesAlgicides
• A01N 43/16 - Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one or more oxygen or sulfur atoms as the only ring hetero atom with one hetero atom six-membered rings with oxygen as the ring hetero atom

Abstract

New pyrimidine derivatives of formula (I), optionally with a detectable isotope, pharmaceutical composition and method of preparation thereof. New pyrimidine derivatives for use in treatment or prevention of bacterial infection in a host mammal in need of such treatment or prevention and use as inhibitors of biofilm formation on a surface of biomaterial or medical device, particularly of cardiovascular device such as prosthetic heart valve or pacemakers. New pyrimidine derivatives for use as radiotracer in diagnosing or prognosing bacterial infection in a host mammal.

IPC Classes  ?

• C07D 473/24 - Heterocyclic compounds containing purine ring systems with oxygen, sulfur, or nitrogen atoms directly attached in positions 2 and 6 one nitrogen and one sulfur atom
• A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
• A61K 31/52 - Purines, e.g. adenine
• A61P 31/00 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
• C07D 473/18 - Heterocyclic compounds containing purine ring systems with oxygen, sulfur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine
• C07D 487/04 - Ortho-condensed systems